Castle Biosciences (CSTL) Q4 2020 earnings summary

Executive summary

• 18,185 genomic test reports delivered in 2020; revenue rose 20.8% YoY to $62.6M despite COVID-related pressure on test volumes.

• Two new dermatology tests launched in 2020, expanding the marketed portfolio to four tests; year-end cash and cash equivalents were $409.9M, with no debt after repayment in December.

• Continued investment in commercial capacity, clinical evidence and pipeline development; potential target of 3–5 additional test launches by end-2025.

Financial highlights

• FY2020 revenue $62.649M, up 20.8% YoY; gross margin $52.964M, up 18.9%, while gross margin rate eased to 84.5% from 85.9%.

• Operating loss was $6.542M versus operating income of $7.328M in 2019; net loss was $10.284M versus net income of $5.277M.

• R&D expense rose 79.5% to $13.256M and SG&A rose 61.3% to $48.132M, reflecting expanded staffing, studies, commercialization and public-company costs.

• Adjusted for timing of variable consideration, prior-period revenue adjustments were net positive $0.176M in 2020 versus $2.493M in 2019; 2020 also included $1.882M CARES Act provider relief income and a $1.397M debt extinguishment loss.

• Basic and diluted FY2020 loss per share were both $0.54; operating cash flow was $9.865M and ending cash and equivalents were $409.852M.

Outlook and guidance

• Expected revenue plan spans near-, mid- and long-term growth; commercial team expansion was planned to finish in H1 2021, reaching approximately 60 outside sales territories.

• Potential launch of 3–5 pipeline tests by end-2025, using current sales channels and potentially adding $3.6B to U.S. addressable market.

• Planned continued evidence development for four marketed tests and investment in clinical studies, including PERSONALize and CONNECTION, the latter collecting long-term outcomes for up to 10,000 tested patients.

• Cash on hand and anticipated product-sale collections were expected to fund operations for the foreseeable future; estimates depend on assumptions, including COVID-19 effects.